Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03431844|
Recruitment Status : Recruiting
First Posted : February 13, 2018
Last Update Posted : February 13, 2018
Objective of the study is to clarify humanin-like peptide concentration in myocard tissue and in blood and to study if its concentration level is related to early complication occurrence and frequency after cardiac operation.
Hypothesis of the study is that previously described elements are related to each other.
|Condition or disease|
|Myocardial Ischemia Coronary Artery Bypass Surgery|
Data collection: Historical medical and preoperative data, operation data (type of operation performed and its details), detailed postoperative course (occurrence of complications).
- Tissue sample is taken during the operation from the right atrial appendage of the heart and the sample is frozen at -80 C.
- Blood samples are taken just before the operation, one hour after aortic cross-clamp removal and the next morning after the operation. Samples are processed and blood plasma is frozen at -80 C.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Prospective Clinical Observational Study of Humanin Isoforms in Cardiac Muscle and Blood Plasma and Their Association to Major Complications After Cardiac Operation|
|Actual Study Start Date :||January 1, 2018|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||June 1, 2019|
- Mortality [ Time Frame: 30 days ]30-day all-cause mortality
- Major complications: myocardial infarction. [ Time Frame: 30 days ]Diagnosed myocardial infarction.
- Major complications: acute kidney injury. [ Time Frame: 30 days ]Diagnosed acute kidney failure (KDIGO stage).
- Major complications: stroke. [ Time Frame: 30 days ]Diagnosed stroke.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03431844
|Contact: Henery Kroon, MDemail@example.com|
|North Estonia Medical Centre||Recruiting|
|Tallinn, Harjumaa, Estonia, 13419|
|Contact: Inga Karu, MD, PhD +3726171196 Inga.Karu@regionaalhaigla.ee|
|Tartu University Hospital||Recruiting|
|Tartu, Tartumaa, Estonia, 51014|
|Contact: Joel Starkopf, MD, PhD +3727318400 firstname.lastname@example.org|
|Contact: Peeter Tähepõld, MD, PhD +3727318432 Peeter.Tahepold@kliinikum.ee|
|Study Director:||Joel Starkopf, MD, PhD||Tartu University Hospital|